Navigation Links
TodayMD Becomes a Google AdWords Authorized Reseller
Date:9/9/2008

Designation Enables TodayMD to Deliver Comprehensive SEM Program to Medical and Dental Clients

Miami, FL (PRWEB) September 9, 2009-- http://www.TodayMD.com [TodayMD], an innovator in online marketing technology and services for medical and dental practices, announced today a strategic relationship with Google to become an authorized reseller of http://www.TodayMDMarketing.com [Google AdWords™]. AdWords is an online advertising program designed to help businesses of all sizes use the Web to find new customers by delivering relevant ads when users search for specific products and services. Expanding their search engine marketing (SEM) program to incorporate the Google AdWords offering enables TodayMD to deliver strong search engine marketing strategies to their medical and dental clients while maximizing their marketing dollars.

With nearly three quarters of internet users using search as part of the research process (1), Google AdWords is an important part of a medical and dental practice's marketing strategy. Advertising on Google's online advertising platform can provide medical and dental advertisers instant access to local patients looking for their services. As a Google AdWords Authorized Reseller, TodayMD's sales force is equipped to help doctors efficiently tap into the power and reach of the AdWords platform.

TodayMD's Managed SEM service includes comprehensive, full-service management of AdWords search advertising campaigns on behalf of doctors. Experienced SEM strategists provide professional account management by creating custom campaigns for each doctor designed to fit the individual client's specific marketing goals and budget. The high-quality customer service also includes ongoing campaign monitoring, measurement and testing to consistentl
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. UHN becomes a world leader in medical imaging for stroke, cancer and cardiac patients
2. Kaiser Permanente Becomes Presenting Sponsor for Pasadena Marathon
3. CollaborateMD Becomes a Habitat for Humanity International HopeBuilder
4. With $2M NIH grant, FSU becomes 1 of worlds top imaging centers
5. Breastfeeding.com Becomes a Premier Resource on Child Health
6. Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
7. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
8. Nursing Home for Sex Offenders Becomes Law, a First in America
9. How advanced prostate cancer becomes resistant to androgen-deprivation therapy
10. Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology
11. UNIVAL, Inc. Becomes a Google Health(TM) Integrated Service
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TodayMD Becomes a Google AdWords Authorized Reseller
TodayMD Becomes a Google AdWords Authorized Reseller
(Date:12/4/2009)... YORK, Dec. 4 Thousands of KPMG LLP employees came ... in a community service event which combines the audit, tax ... ,, "This national service day reflects our firm,s long history ... the spirit of caring to brighten the holidays for some ...
(Date:12/4/2009)... Allied World Assurance,Company Holdings, Ltd (NYSE: ... Executive Officer, and Jack Sennott, Executive Vice,President and Chief ... Sachs U.S. Financial Services Conference being held at the ... December 8, 2009. ,, About ...
(Date:12/4/2009)... Dec. 4 Healthcare Trust of America, Inc. ("HTA"), ... execution of a purchase and sale agreement to acquire ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... subject to the satisfaction of a number of conditions. ...
(Date:12/4/2009)... Mich., Dec. 4 The Editorial Advisory and Securities Review ... Inc. (NYSE: AGN ) as its February ... (NYSE: BCR ) as its February 2010 "Undervalued ... chose Allergan because of growth opportunities involving its flagship drug ...
(Date:12/4/2009)... whether health care reform would control health care ... that lead through example -- delivering the best ... highest levels of efficiency. Thirty-four urban, eight children,s ... Leapfrog Top Hospitals, based on results from The ...
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
... Forest Laboratories, Inc.,(NYSE: FRX ), an international ... Fiscal 2008 Third Quarter financial results,before the U.S. ... Later that,day, at 10:00 AM EST, Forest will ... and Chief Operating Officer and Frank Perier, Senior,Vice ...
... Torchmark Corporation,(NYSE: TMK ) announced today ... subsidiaries, United American Life Insurance Company, and Globe,Life ... Torchmark,plans to redomesticate other of its subsidiaries to ... in a number of states, as well as ...
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ... received final approval from the,United States (U.S.) Food ... Application (ANDA) for Ipratropium Bromide and Albuterol Sulfate,Inhalation ... Watson,s Ipratropium Bromide and Albuterol Sulfate product is ...
... Roxane Laboratories, Inc.,announced today the approval ... Granisetron Hydrochloride Tablets, 1mg by the U.S. ... in Unit Dose Blisters and is,available for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO ), ...
... Bedford Laboratories(TM), a,division of Ben Venue ... citrate) Injection and CAFCIT(R) (caffeine citrate),Oral Solution ... is now the,reference listed drug holder. CAFCIT(R) ... treatment of apnea in premature infants between ...
... which children are at risk for malignancy, experts say ... scientists have discovered that children who have cancer also ... curvature of the spine. , This suggests that the ... anomaly, raising hopes that genetic information may help identify ...
Other Medicine News:Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings 2Health News:Watson Receives FDA Approval for Generic DuoNeb(R) 2Health News:Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg 2Health News:Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution 2Health News:Body Abnormalities, Childhood Cancer May Share Genes 2Health News:Body Abnormalities, Childhood Cancer May Share Genes 3
(Date:12/4/2009)... Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the ... US Patent and Trademark Office has allowed its patent ... stages of the manufacture of the Company,s DCVax® therapeutic ... to the very high concentration of dendritic cells (which ...
(Date:12/3/2009)... Pa., Dec. 3 Ambry Genetics and SoftGenetics ... provide extended bioinformatics genomics services using SoftGenetics, NextGENe ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO ) ... team at Ambry has been providing genomics solutions ...
(Date:12/3/2009)... imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration ... North America in Chicago. The Connect.PACS(TM) ... of its kind, is the latest release in ... . ,, (Photo: http://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
Breaking Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3deCODE Receives Delisting Notice From Nasdaq Plans to Appeal 14968 1deCODE Receives Delisting Notice From Nasdaq Plans to Appeal 14968 2deCODE Receives Delisting Notice From Nasdaq Plans to Appeal 14968 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 6516 1Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 6516 2Dangerous Toys Still on Store Shelves Report Finds 62059 1Dangerous Toys Still on Store Shelves Report Finds 62059 2Dangerous Toys Still on Store Shelves Report Finds 62059 3
... Minimal Weight Change Reported Unlike What Is Commonly ... – Novo Nordisk today announced,results of a new ... insulin Levemir® (insulin detemir [rDNA origin],injection). Patients ... own dosage of Levemir® and achieve improvements in ...
... 2007 - New data from an,investigational study ... Annual Scientific Sessions showed that initial,combination therapy ... in markers of beta cell,function in patients ... function determines the ability of the body ...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32
... test face is the most widely used contrast ... for four (4) rows of sine-wave gratings. At ... meters), these gratings test the spatial frequencies of ... provides a full contrast sensitivity curve, which is ...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
... Ergogenic aids, anabolic steroids, running, shoe ... tennis, common sports problems, the female ... athletes, exercise, exercise (treadmill) stress testing ... illness, acclimatization, neuropraxia, overtraining syndrome, management ...
Medicine Products: